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Objective: To determine exactly how German and Austrian routine laboratories perform tests for the identification of 
enterococci and determination of their glycopoptide resistance. 
Methods: Six enterococcal test strains with different types of glycopeptide resistance (Enterococcus faecium, VanA; E. 
faecalis, VanA; E. faeciurn, VanB; E. faecalis, VanB; E. gallinarum, VanC1; E. casseliflavus, VanC2) were sent as anonymous 
isolates to  73 clinical microbiology laboratories (65 in Germany; eight in Austria). The participating laboratories had to  
identify the strains up  t o  the species level and t o  determine their antibiotic susceptibilities to  the glycopeptides 
vancomycin and teicoplanin by the test method(s) that are used daily in  the corresponding laboratories. 
Results: The analysis of the results received from 62 laboratories (56 from Germany, six from Austria) demonstrated 
that the most used routine method in  susceptibility testing was the agar diffusion test, followed by the Etest, and the 
microbroth dilution procedure. The majority of participants had no difficulties in  susceptibility testing with the VanA- 
type strains. However, the agar diffusion test was often not able to  recognize clearly the VanB and VanC strains; some 
problems also arose with VanB isolates in the Etest. With the microbroth dilution method, the corresponding type of 
glycopeptide resistance was correctly determined in the majority of enterococcal test strains. Difficulties also arose in 
identification, especially with the VanC strains (E. gallinarum and E. casseliflavus), which were often falsely identified as 
E. faecium. The reasons for these errors are obviously based on  the lack of important tests (such as motility and presence 
of a yellow pigment) in  some commercially available identification test kits. 
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INTRODUCTION 
The emergence of glycopeptide resistance in entero- 
cocci threatens the chemotherapy of enterococcal 
infections, especially in Enterococcrts fuecitrm, where 
resistance to ampicillin is frequent. The incidence of 
glycopeptide-resistant enterococci (GRE) has increased 
remarkably during the last 10 years in US hospitals (up 
to 16% in intensive care units and up to 12% in other 
hospital units in 1997 [l]). Although less frequent, 
serious but sporadic hospital infections and nosocomial 
outbreaks with G R E  have also been reported in 
Europe, including Germany [2] .  Correct detection of 
glycopeptide resistance in the clinical laboratory is a 
prerequisite for chemotherapy and prevention of noso- 
comial spread. 
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The NCCLS has recently published its latest 
minimal inhibitory concentration (MIC) interpretative 
criteria for glycopeptides [3], which also correspond 
approximately to the DIN standard [4]. 
In enterococci, six different genotypes of glyco- 
peptide resistance are known: tmA mediates high-level 
vancomycin resistance (with MIC 2128 mg/L in most 
isolates); also, for tlanD, MICs for vancomycin above 
32 mg/L have been described [5,6]. For t m B ,  the 
vancomycin MICs are in the range of the breakpoint; 
however, they can also be up to 1024 mg/L [5]. The 
vunA gene cluster also mediates resistance to teicoplanin 
whereas vunB and vunD do not. The three intrinsic 
vanC genotypes (vunC1, imCz, ttznC3) o f  particular 
enterococcal species (E. gullinarum, E. cassel$uvus, E.  
Juvescens) confer low-level resistance to vancomycin 
(and, simultaneously, susceptibility to teicoplanin [5]) 
with no clinical significance. However, there are also 
reports concerning strains of these latter species that 
were high-level glycopeptide resistant as a result of 
picking up the vunA gene cluster [7]. 
Two previous studies, one in the UK and one in 
the USA [8,9], revealed that detection of resistance 
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genotypes other than vanA in the clinical laboratory can 
be problematic; only 5040% of GRE with the vanB 
genotype were classified as resistant to vancomycin. 
The present study reports on the capacity of German 
and Austrian clinical microbiology laboratories to 
correctly detect GRE. 
MATERIALS AND METHODS 
Study design 
Six GRE strains possessing different genotypes of 
glycopeptide resistance were sent as anonymous isolates 
to 73 laboratories (65 in Germany, eight in Austria), 
where they were checked. The characteristics of these 
strains are shown in Table 1; the genotypes of glyco- 
peptide resistance had been demonstrated by poly- 
merase chain reaction [lo]. 
The laboratories performed bacterial identification 
and antibiotic susceptibility testing according to their 
routine procedures. They returned a questionnaire on 
the species detected, the results from the susceptibihty 
test method used (difision zones in agar difision test, 
MICs in dilution methods and in Etest), the criteria 
applied for interpretation, and the derived susceptibility 
category. 
The laboratory data received from the participants 
were analyzed by comparison with the known entero- 
coccal species and their glycopeptide susceptibilities, 
and are summarized in Tables 2 and 3. 
RESULTS 
Of the 73 clinical microbiology laboratories that 
received the enterococcal strains, 62 (56 from Germany 
and six &om Austria) returned the questionnaires with 
their test results for analysis (85%). Most of the 62 
institutions applied one definite susceptiblity method, 
but some performed up to four. 
The majority of the participating laboratories had 
used the agar diffusion test (Table 2). When VanA 
strains were tested for vancomycin, they were always 
classified correctly. In contrast, when VanA isolates 
were tested for teicoplanin, E. faecium was classified 
correctly as resistant by all laboratories, but E. faecalis 
was classified correctly in only 74% of cases. 
Additionally, the agar difision test often failed to 
class* VanB strains correctly (especially when testing 
vancomycin). The Etest classified the E .  jiecium VanA 
type strain 70/90 correctly; about one-third of the 
laboratories determined the VanA E. jiecalis isolate 
1528 as intermediate or susceptible to teicoplanin by 
this method. For the detection of VanB strains, the 
Etest performed slightly better than the agar difhsion 
test (especially in the case of vancomycin). With vanco- 
mycin and teicoplanin MICs originating h m  micro- 
broth dilution test v a d -  and vanBencoded resistance 
in enterococci were detected most often correctly in 
comparison to the other tests checked (Tables 1 and 2). 
Within the group of VanC strains, a broad range of 
in-vitro resistance and susceptibility against vanco- 
mycin was determined with all antibiotic susceptibility 
methods by the participants (Table 2). The teicoplanin 
susceptibility of the VanC strains was determined cor- 
rectly by nearly all participants (Tables 1 and 2). 
Some difficulties also arose in bacterial identifi- 
cation of the six test strains (with the exception of E. 
faeculis 1528; see Table 3). The majority of false 
identifications occurred with the VanC isolates: E. 
gallinarum UW 701/95 was correctly identified in only 
36%, and E. casselijlavus UW 703/95 in 59%. Addition- 
ally, in both VanC strains, a broad spectrum of false 
species was determined (Table 3). However, a small 
number of laboratories also falsely identified E. faecalis 
UW 700/95 and the E,faecium strains (Table 3). 
DISCUSSION 
Glycopeptides such as vancomycin and teicoplanin are 
important 'reserve' antibiotics for treatment of infec- 
tions with ampicillin-resistant enterococci or in cases of 
Table 1 Characterization of test strains with different genotypes of glycopeptide resistance used in the ring study 
Resistance phenotype: MIC (mg/L) and antibiotic 
susceptibility category (S, I, R)" for the glycopeptides Genotype of 
glycopepdde 
Species Strain no. Vancomycin Teicoplanin resistance 
E. faen'um 70/90 512-1024 (R) 128-256 (R) vanA 
E. faecium UW 699/95 16-128 (R) 0.25-1 ( S )  vanB 
E .  faecalis UW 700/95 32-256 (R) 0.25-1 ( S )  vanB 
E. gallinarum UW 701/95 8-16 (I-R) 0.25-1 (S) VanCj 
E .  casselijlavus UW 703/95 4-8 (S-I) 0.25-1 ( S )  vanCz 
" S ,  sensitive; I, intermediate; R, resistant. 
E.  faecalis 1528 256-512 (R) 64-128 (R) V a d  
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Table 2 Reports h m  62 clinical microbiology laboratories on classification of glycopeptide susceptibility for six 
enterococcal control strains tested 
Vancomycin Teicoplanin 
Agar Microbroth *gar Microbroth 
di€fusion dilution Etest dihsion dilution Etest 
Strain Genome Data' S I R S I R  S I R  S I R  S I R  S I R  
E .  faen'um uanA 1 35 20 24 32 18 17 
70190 2 - -  35 - - 2 0  - -  24 - - 32 - - 18 - - 17 
3 - - (100) - - (100) - - (100) - - (100) - - (100) - - (100) 
E. faecufis uanA 1 34 20 23 31 18 16 
1528 2 - -  34 - - 2 0  - -  23 3 5 2 3  - 3 1 5  2 3 1 1  
3 - - (100) - - (100) - - (100) (10) (16) (74) - (17) (83) (13) (18) (69) 
E .  faecium vanB 1 35 20 24 32 17 17 
UW 699/95 2 1 6 5  14 1 2 1 7  2 6 1 6  2 8 3  1 1 7 -  - 1 7 -  - 
3 (46) (14) (40) (5) (10) (85) (8) (25) (67) (88) (9) (3) (100) - - (100) - - 
E .  faecufis vanB 1 35 20 24 32 17 17 
UW 700/95 2 1 2 7  16 1 - 19 7 2 15 3 1 1  - 1 7 -  - 1 6 -  1 
3 (34) (20) (46) (5) - (95) (29) (8) (63) (97) (3) - (100) - - (94) - (6) 
E .  gallinarum vanCf 1 35 20 24 32 17 17 
UW 701/95 2 2 2 8  5 5 9 6 6 1 2 6  3 1 1  - 1 7 -  - 1 7 -  - 
3 (63) (23) (14) (25) (45) (30) (25) (50) (25) (97) (3) - (100) - - (100) - - 
E.  carsefijlavus vanCr 1 35 20 24 32 17 17 
UW 703/95 2 3 3 2  - 1 4 2  4 1 4 8  2 3 1 1  - 1 6 1  - 1 7 - -  
3 (94) (6) - (70) (10) (20) (59) (33) (8) (97) (3) - (94) (6) - (100) - - 
"Data: 1, total number of laboratories performing the test: 2, classification as sensitive, intermehate, resistant (&om left to right); 
3, percentage (in parentheses). 
The correct classification groups are in bold type. 
Table 3 Identification of six enterococcal test strains by 58 clinical-microbiological laboratories from Germany and Austria 
E .  E.  E .  E .  E.  E. E .  E .  Enterococcus Lactoroms Aerococcus 
Strain Genotype faerium feculis galfinarum cassefijlavus flauesceus durans auium porcinlrs spp. lactis mutans 
- - - - 1 - 1 1 E. faecium vanA 55 - - 
70/90 (94) - (2) (2) - 
E.  faecualis vanA - 
1528 - (100) - 
E .  faecium vanB 53 1 2 1 - - 
UW 699/95 (91) (2) (3) (2) 
UW 700/95 (2) (96) - 
uw 701/95 (24) (3) (36) (33) (2) - (2) 
- - (2) - - - 
- - - - - - - - 58 
- - - - - - - - 
- - 1 - - 
- - - - - (2) - 
- - - - - - - 1 E .  Jaecalis v u f a  1 56 - 
- - - (2) - - 
1 1 E .  gallinarum vanCl 14 2 21 19 - - - - - 
- - - - 
The correct enterococcal species are indicated by bold type 
penicillin allergy. Enterococci of the VanA type are 
cross-resistant between vancomycin and teicoplanin. 
This type is the most common and clinically most 
important. In contrast, infections by VanB- and VanC- 
type strains can be treated with teicoplanin. Thus, 
susceptibility testing to vancomycin and teicoplanin 
should be performed. In this connection, the correct 
species identification can give valuable indications on 
the corresponding type of glycopeptide resistance: the 
VanC types are characterized by low-level vancomycin 
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resistance as a species property of E.  gallinarum (VanCi), 
E.  casseliflavus (Van&), and E. flavescens (vanC3). 
However, there also exist hgh-level vancornycin/ 
teicoplanin-resistant VanC strains [7]. 
Among the different antibiotic susceptibility 
methods used by the participants of this study, the 
agar difhsion test was the most common. However, in 
the German description for this test [ll], the agar 
diffusion test is not recommended for the susceptibility 
testing of glycopeptides because of its bad correlation 
between inlbitory zones and the corresponding MICs. 
Here, dilution tests (e.g. the microbroth dilution 
method [3,12]) are recommended. Nevertheless, it 
must be noted that the resistance to vancomycin in 
VanB strains can be expressed at very different levels; 
for example, the MICs can range between 4 and 
1024 mg/L [5], but for the majority of strains they are 
16-32 mg/L. Thus, VanB isolates and also (low-level 
resistant) VanC strains are not easy to detect. Difficulties 
with the agar diffusion test in determining vancomycin 
resistance in enterococci (especially of the VanB or 
VanC type) have also been described by other authors 
[8,9,13-161. The majority of these authors, however, 
reported no problems in cases of the high-level glyco- 
peptide resistance type VanA. Concerning the Etest, 
there are different experiences reported in the liter- 
ature: Endtz et al [13] could detect all enterococci 
correctly, including the VanB- and VanC-type GRE; in 
contrast, Schulz and Sahm [16] reported that the Etest 
must be interpreted with caution in these enterococcal 
species. It remains open whether the laboratories par- 
ticipating in our study correctly followed the manu- 
facturer’s recommendations for the Etest with regard to 
the bacterial inoculum and the time of incubation (at 
least 24 h). Furthermore, weak growth within the 
inhibition zones has to be considered for detection of 
VanB-type GRE (A. Bolmstrom, personal communi- 
cation). To be totally sure, in critical cases (besides an 
exact enterococcal species determination), MICs 
should be determined by microbroth dilution, e.g. by 
using fiozen or lyophilized MIC rows for vancomycin 
and teicoplanin (e.g. by MIC rows from Feinchemie 
Sebnitz GmbH, Germany [17]), and additionally the 
PCR for the corresponding van gene(s) should be 
performed (e.g. by multiplex PCR [IS]). With the 
Vitek automated system and other methods (agar 
dilution, rapid microbroth dilution) that were rarely 
used in the present study (one or two laboratories used 
one of these three methods per test strain), we could 
not derive a classification. However, other authors 
observed a substantial influence of the growth medium 
used on the expression of the vancomycin resistance in 
the Vitek test (191; for example, these authors found 
that the brain-heart infusion broth used in this test can 
support good enterococcal growth but does not 
sufficiently support the expression of glycopeptide 
resistance among certain strains. From our point of 
view, the microbroth ddution test seems to be the most 
correct method in daily routine use for determining the 
exact type of enterococcal glycopeptide resistance at 
the present time. In this connection, the detection of 
enterococcal glycopeptide resistance genes by PCR can 
be a valuable confirmation. 
Enterococci of the E.  gallinarum group (E.  gallin- 
arum, E .  casseliflavus, E .  flavescens) are all motile and- 
with the exception of E. gallinarum-also yellow pig- 
mented [ZO]. However, tests for these characteristics are 
often not included in commercially available identifi- 
cation systems (e.g. API STREP). This fact also explains 
the differences in species determination of the VanC 
strains (e.g. as ‘E.  casseliflavus’ misidentified as E.&ecium 
strains). However, by testing these two reactions one 
can adequately discriminate ths group of enterococci 
from other enterococcal species. Thus, tests for motility 
and presence of the yellow pigment should be included 
in commercial identification systems. 
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